Home / Market News / $NYXH
benzinga Corporate Catalyst Impact 75/100 ● positive

Nyxoah Reports Preliminary Q3 Global Net Sales Of ~€9.2M, Up 19% QoQ; Lowers FY26 Global Net Sales From €36M-€40M To €33M-€35M

Oct 19, 2026, 12:05 PM UTC · Primary ticker $NYXH

Nyxoah reported preliminary Q3 2026 global net sales of approximately €9.2 million, a 19% sequential increase. However, the company significantly lowered its full-year 2026 global net revenue guidance from €36M-€40M to €33M-€35M, indicating a slowdown in expected growth despite positive Q3 performance and clinical milestones.

Nyxoah reported preliminary Q3 2026 global net sales of €9.2 million, showing strong sequential growth. However, the company simultaneously lowered its full-year 2026 revenue guidance by approximately 8-12% at the midpoint. This downward revision, despite positive Q3 sales and clinical progress (successful ACCCESS study, FDA submission for CCC patients), suggests that the company's previous growth projections were overly optimistic or that there are underlying challenges impacting future sales. This is a negative signal for investors, as it indicates a potential deceleration in the company's growth trajectory or increased market headwinds. Short-term, this could lead to a negative stock reaction due to reduced revenue expectations. Long-term, the impact will depend on whether the company can meet its revised guidance and capitalize on its clinical advancements.

$NYXH negative Lowered revenue guidance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.